Publicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (29)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

2023

  1. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database

    Rheumatology (Oxford, England), Vol. 62, Núm. 4, pp. 1559-1567

  2. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

    The Lancet Rheumatology, Vol. 2, Núm. 2, pp. e71-e83

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

    Rheumatology International, Vol. 39, Núm. 11, pp. 1875-1882

2018

  1. Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations

    PLoS ONE, Vol. 13, Núm. 1

2017

  1. An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis

    Journal of Rheumatology, Vol. 44, Núm. 10, pp. 1453-1457

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

    Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345

  2. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis

    Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 238-245

  3. Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus

    Arthritis and Rheumatology

  4. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

    American Journal of Human Genetics, Vol. 94, Núm. 1, pp. 47-61

  5. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2